Mohebat Vali

Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis

Abstract Background Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequently leads to late diagnosis. Survival rate of patients diagnosed with ovarian cancer can be used in order to better assess current standard of care; the aim of this study is to evaluate the survival rate of ovarian cancer patients in Asia. Methods Systematic review was performed on articles that were published by the end of August 2021 in five international databases, including Medline / PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar. The Newcastle-Ottawa quality evaluation form was used for cohort studies to evaluate the quality of the articles. The Cochran-Q and I2 tests were used to calculate the heterogeneity of the studies. The Meta-regression analysis was also done according to when the study was published. Results A total of 667 articles were reviewed, from which 108 were included in this study because they passed the criteria. Based on a randomized model, the survival rates of ovarian cancer after 1, 3 and 5 years were respectively 73.65% (95% CI, 68.66–78.64), 61.31% (95% CI, 55.39–67.23) and 59.60% (95% CI, 56.06–63.13). Additionally, based on meta-regression analysis, there was no relationship between the year of study and survival rate. Conclusions The 1-year survival rate was higher than that of 3- and 5-year for ovarian cancer. This study provides invaluable information that can not only help establish better standard of care for treatment of ovarian cancer, but also assist in development of superior health interventions for prevention and treatment of the disease.

Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis

Abstract Objective Cancer is one of the main causes of death, and cervical cancer is the fourth most common cancer and the fourth leading cause of death from malignancy among women. Knowing the survival rate is used to evaluate the success of current treatments and care. This study was conducted to assess the survival rate of cervical cancer in Asia. Methods This systematic survey was conducted on four international databases, including Medline/PubMed, ProQuest, Scopus, and Web of Knowledge, and includes manuscripts that were published until the end of August 2021. Selected keywords were searched for international databases including cervical neoplasms [mesh], survival analysis or survival or survival rate, Asian countries (name of countries). The Newcastle-Ottawa Qualitative Evaluation Form was used for cohort studies to evaluate the quality of the articles. The analysis process was performed to evaluate the heterogeneity of the studies using the Cochran test and I2 statistics. Additionally, a meta-regression analysis was performed based on the year of the study. Results A total of 1956 articles were selected and reviewed based on their title. The results showed that 110 articles met the inclusion criteria. According to the randomized model, the 1, 3, 5, and 10-year survival rates of cervical cancer were 76.62% (95% Confidence Interval (CI), 72.91_80.34), 68.77% (95% CI, 64.32_73.21), 62.34% (95% CI, 58.10_66.59), and 61.60% (95% CI, 52.31_70.89), respectively. Additionally, based on the results of meta-regression analysis, there was an association between the year of the study and the survival rate, elucidating that the survival rate of cervical cancer has increased over the years. Conclusions Results can provide the basic information needed for effective policy making, and development of public health programs for prevention, diagnosis, and treatment of cervical cancer.

Brain Metastases in Cervical Cancer: A Global Systematic Review and Meta‐Analysis of Incidence and Clinicopathological Features

ABSTRACT Background Cervical cancer (CC) remains the fourth most prevalent malignancy among women globally, with a disproportionate burden in low‐ and middle‐income countries, where it is often diagnosed at advanced or metastatic stages. Aims Despite an increasing number of case reports and institutional studies on brain metastases (BMs) arising from CC, current understanding of their epidemiology, clinical presentation, and prognostic implications remains fragmented and lacks comprehensive synthesis. Methods We executed a systematic and unrestricted search of five major databases, PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar, covering all records up to April 19, 2025. Studies were eligible for inclusion if they provided a clear report on the incidence of BMs among CC patients. The quality and risk of bias of the selected studies were independently appraised using the Joanna Briggs Institute (JBI) assessment criteria. For statistical analysis, we utilized STATA version 17, implementing random‐effects meta‐analytical models to estimate the aggregated incidence along with corresponding 95% confidence intervals (CIs). Results A total of 17 studies encompassing 33 datasets were included in the final analysis. The global pooled incidence of BMs among cervical cancer patients was estimated at 0.65% (95% CI: 0.46–0.85). Incidence was highest in Turkey (1.83%, 95% CI: 0.91–2.75) and lowest in South Africa (0.22%, 95% CI: 0.0–0.47). Among histologic subtypes, neuroendocrine carcinoma exhibited the highest pooled incidence of BMs at 10.60% (95% CI: 0.0–21.63), followed by adenocarcinoma at 0.89% (95% CI: 0.14–1.64). The pooled mean survival time following the diagnosis of BMs was 6.80 months (95% CI: 5.08–8.52), while the mean interval from the initial cervical cancer diagnosis to the development of BMs was 28.15 months (95% CI: 24.27–32.03). Conclusion Although BMs in cervical cancer are rare, they are associated with dismal survival outcomes and poor prognosis. These findings underscore the importance of vigilant surveillance in high‐risk patients and may inform the development of more targeted and effective therapeutic and preventive strategies.